Micromet said data from its completed Phase II clinical trial showed a high response rate of blinatumomab in patients with acute lymphoblastic leukaemia (ALL).

A total of 21 patients with ALL, who had all undergone extensive chemotherapy and had malignant cells persisting in their bone marrow, were treated with blinatumomab.

The endpoint of the trial was the elimination of these cancer cells to an undetectable level in at least 22% of patients.